Our Pricing

Semaglutide Wegovy: Evidence-Based Weight Loss Treatment Available Online UK

Published on: June 03, 2026

When you buy semaglutide Wegovy online UK through Cured Pharmacy, you're accessing a clinically proven GLP-1 receptor agonist that helped patients achieve an average 14.9% body weight reduction in the landmark STEP trials [1]. Our UK-registered clinical team provides free consultations in under three minutes, with transparent pricing from £79.00 and discreet next-day delivery across the UK.

How Semaglutide (Wegovy) Works for Weight Loss

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics a natural hormone your body produces after eating [1]. By activating GLP-1 receptors in the brain, pancreas, and digestive system, Wegovy reduces appetite, slows gastric emptying, and improves blood sugar regulation—creating the metabolic conditions that support sustained weight loss.

In the STEP 1 clinical trial involving 1,961 adults with obesity, participants receiving once-weekly semaglutide 2.4mg injections achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% in the placebo group [1]. Importantly, 86.4% of semaglutide-treated patients achieved at least 5% weight loss, and 69.1% reached the 10% threshold—outcomes rarely seen with lifestyle interventions alone [1].

Semaglutide has been licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [2]. At Cured Pharmacy, our UK prescribers assess your eligibility during a confidential online consultation, ensuring semaglutide is clinically appropriate for your individual circumstances.

Wegovy vs Mounjaro: Comparing Semaglutide and Tirzepatide

Both Wegovy and Mounjaro are once-weekly injectable treatments licensed in the UK for weight management, but they work through different receptor pathways. Semaglutide activates GLP-1 receptors exclusively, while tirzepatide (the active ingredient in Mounjaro) is a dual GIP/GLP-1 receptor agonist—targeting two complementary hormone pathways simultaneously [3].

Head-to-head trial data suggests tirzepatide may produce slightly greater weight loss on average. In the SURPASS-2 study, participants on tirzepatide 15mg achieved mean weight reductions of 11.2kg compared to 5.7kg with semaglutide 1mg over 40 weeks [3]. However, direct comparisons are complicated by different trial populations, dosing schedules, and baseline characteristics.

Your choice between semaglutide and tirzepatide should be guided by clinical factors including your weight loss goals, tolerance of gastrointestinal side effects, previous treatment response, and budget considerations. Our UK prescribers at Cured Pharmacy review your medical history and preferences to recommend the most suitable option, with transparent pricing displayed before your consultation begins.

Which Treatment Is Right for You?

Semaglutide may be preferred if you're seeking a well-established treatment with extensive real-world safety data spanning multiple years, or if you've previously responded well to GLP-1 therapies like Saxenda. Tirzepatide might be considered if you require more intensive weight reduction or have not achieved adequate results with semaglutide-based treatments, subject to prescriber assessment and clinical suitability.

Wegovy Dosing Schedule and What to Expect

Wegovy follows a gradual dose escalation protocol designed to minimise gastrointestinal side effects while optimising weight loss efficacy [2]. You'll begin with a 0.25mg subcutaneous injection once weekly for four weeks, then increase monthly through 0.5mg, 1mg, and 1.7mg doses before reaching the maintenance dose of 2.4mg by week 17.

This stepwise titration allows your body to adapt to semaglutide's effects on gastric motility and appetite regulation. Most patients experience the greatest appetite suppression and weight loss velocity once they reach the 1.7mg or 2.4mg maintenance doses [1]. If you experience persistent nausea or vomiting at any stage, your prescriber may recommend staying at your current dose for an additional four weeks before advancing.

Wegovy is administered via a pre-filled single-dose pen injected subcutaneously into your abdomen, thigh, or upper arm. Rotate injection sites weekly to reduce the risk of lipodystrophy. Store unused pens in the refrigerator between 2°C and 8°C, and never freeze. Once removed from refrigeration, pens may be kept at room temperature (up to 30°C) for up to 28 days.

Timeline for Weight Loss Results

Most patients begin noticing reduced appetite and early weight loss within the first 4-8 weeks of treatment, with more substantial changes becoming apparent after reaching higher maintenance doses [1]. In clinical trials, the average rate of weight loss was approximately 1% of body weight per week during the first 20 weeks, then gradually plateaued as patients approached their individual set point [1]. Combining semaglutide with a reduced-calorie diet and increased physical activity optimises outcomes—NICE guidance recommends reviewing treatment at 6 months and discontinuing if less than 5% weight loss has been achieved [2].

Common Side Effects and How to Manage Them

Gastrointestinal symptoms are the most frequently reported side effects of semaglutide, affecting up to 44% of patients in clinical trials [1]. Nausea, diarrhoea, vomiting, constipation, and abdominal discomfort typically emerge during dose escalation phases and often resolve within several weeks as your body adjusts to treatment.

To minimise GI side effects, eat smaller, more frequent meals rather than large portions, avoid high-fat or heavily spiced foods, and stay well-hydrated throughout the day. Taking semaglutide on the same day each week and avoiding dose increases when experiencing persistent nausea can improve tolerability. If symptoms become severe or don't improve after four weeks at a stable dose, contact your prescriber—they may recommend delaying your next dose increase or temporarily reducing your dose.

Rare but serious adverse effects include pancreatitis (characterised by severe persistent abdominal pain radiating to the back), gallbladder disease, acute kidney injury in patients with severe dehydration, and hypoglycaemia when used alongside insulin or sulfonylureas [2]. Semaglutide carries a boxed warning in some jurisdictions regarding thyroid C-cell tumours observed in rodent studies, though no causal link has been established in humans. It should not be used in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [2].

Who Can Use Wegovy Semaglutide in the UK

Wegovy is licensed in the UK for adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater in the presence of at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease [2]. NICE guidance recommends considering GLP-1 receptor agonists like semaglutide as part of a specialist weight management service, alongside dietary modification, increased physical activity, and behavioural support.

Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, or previous serious hypersensitivity reactions to semaglutide or any excipients [2]. It should be used with caution in patients with a history of pancreatitis, severe gastrointestinal disease, renal impairment, or diabetic retinopathy. Semaglutide is not recommended during pregnancy or breastfeeding—women of childbearing potential should use effective contraception and discontinue treatment at least two months before a planned pregnancy.

At Cured Pharmacy, every prescription for Wegovy requires completion of a clinical assessment by a UK-registered prescriber. Our online consultation takes under three minutes and covers your medical history, current medications, weight loss goals, and any contraindications. Superintendent Pharmacist Tarun Kumar (GPhC 2233073) and our clinical team review each case individually to ensure semaglutide is safe and appropriate for you.

Eligibility Assessment Process

Your online consultation will ask about your current weight and height, previous weight loss attempts, relevant medical conditions including thyroid disorders and pancreatitis history, current medications, and any history of eating disorders or mental health conditions. Our prescribers may request additional information or recommend alternative treatments if semaglutide is not clinically suitable. Once approved, your prescription is dispensed from our UK-registered pharmacy and dispatched via next-day delivery in discreet, unmarked packaging.

Why Choose Cured Pharmacy for Semaglutide Wegovy

Cured Pharmacy is a fully registered UK online pharmacy (GPhC registration 9012511) committed to providing genuine, MHRA-licensed medications at transparent, competitive prices. Unlike many online providers, we display exact pricing upfront—before you begin your consultation—so there are no hidden fees or unexpected charges at checkout.

Every prescription is reviewed by our UK-registered clinical team, and all consultations are conducted in accordance with General Pharmaceutical Council standards. We source Wegovy directly from licensed UK wholesalers, guaranteeing authenticity and proper cold-chain storage throughout the supply chain. Your medication arrives in discreet packaging via next-day courier, with full patient information leaflets and guidance on injection technique, storage, and disposal.

Our service includes ongoing support from our pharmacy team. If you experience side effects, have questions about dosing, or need to adjust your treatment plan, you can contact us by phone on (+44) 116 4646009 or via our online portal. We also offer repeat prescription services with automated reminders, ensuring you never miss a dose and can maintain consistent progress toward your weight loss goals.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity (TA875). NICE. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
3. Frías, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
4. Wilding, J. P. H., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564. https://doi.org/10.1111/dom.14725 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to treatment, dietary modifications, and lifestyle factors.